Kintara Therapeutics, Inc. NASDAQ: KTRA

Our Fight Against Cancer Kintara Therapeutics is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara Therapeutics has teamed up with outstanding academic and clinical research institutions from around the world to support the development of our novel cancer therapies. A Pipeline of Breakthrough Cancer Therapeutics VAL-083 is a first-in-class small molecule DNA-targeting agent that exhibits a novel mechanism of action that results in DNA double strand breaks and cancer cell death. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types. VAL-083's indications include: Glioblastoma Multiforme (GBM) Ovarian Cancer Pediatric CNS Tumors REM-001 is a second generation photosensitizer drug possessing multiple advantages over earlier generation PDT compounds. REM-001’s indications include: Cutaneous Metastatic Breast Cancer Recurrent Basal Cell Carcinoma Nevus Syndrome Hemodialysis Arteriovenous (AV) Access

Website

https://www.kintara.com/

External link for Kintara Therapeutics, Inc. NASDAQ: KTRA

Industry

Biotechnology Research

Company size

11-50 employees

Headquarters

San Diego, California

Type

Public Company

Specialties

Cancer, Glioblastoma Multiforme, GBM, Ovarian Cancer, Pediatric CNS Tumors, Cutaneous Metastatic Breast Cancer, Recurrent Basal Cell Carcinoma Nevus Syndrome, and Hemodialysis Arteriovenous (AV) Access